PRC
TVTX icon

Pearl River Capital’s Travere Therapeutics TVTX Stock Holding History

Pearl River Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-205
Closed -$5K – 778
2018
Q4 		$5K Buy
+205
New +$5.1K 0.02% 721

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pearl River Capital's TVTX Position: Q1 2019 in Review

Pearl River Capital sold out of Travere Therapeutics (TVTX) in Q1 2019, closing a stake of 205 shares — an estimated $5K sold.

Pearl River Capital first reported a position in TVTX in Q4 2018 and held it in 1 quarter. The position peaked at $5K in Q4 2018. 131 funds tracked by Wall St. Rank hold TVTX as of Q1 2019.

  • Pearl River Capital reported no remaining Travere Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Pearl River Capital sold 205 Travere Therapeutics shares in Q1 2019, an estimated $5K.
  • Pearl River Capital first reported a position in Travere Therapeutics in Q4 2018 and held it in 1 quarter.
  • Pearl River Capital's Travere Therapeutics position peaked at $5K in Q4 2018.
  • 131 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.